D. Dingli, M-Y Jung, C. P. Offord, et al. Cancer Research, August 2018

Data from high-resolution imaging suggest that methods that enable the quantitation of in vivo anisotropies are required for continuing development of successful oncolytic virotherapies. 

Fig.1: High-resolution U-SPECT/CT imaging of intratumoral isotope uptake in 5mm tumor. In (i) a control tumor has no isotope activity, whereas two representative tumors (ii and iii) infected with MV expressing NIS concentrate the isotope above background. Click here for the full article.

Fig. 2: In another article of Mayo Clinic (A. Miller & S. J. Russell, Expert Opin. Biol. Ther.16(1):15-32) demonstrate that high-resolution nuclear imaging is required in order to identify intratumoral infected oncolytic viral centers required to optimize oncologic treatment. Click here for the full article.

Summary of  VECToradvantages for whole-body tumor micro-environment imaging:

  • The only system that can image all available radiotracers for NIS-mediated imaging at high resolution: 123I, 124I, 125I, 131I, 18F-tetrafluoroborate, 99mTc-pertechnetate, and 188Re.
  • With a single acquisition, it is possible to directly compare the spatiotemporal resolution of PET and SPECT tracers such as 124I/18F, 123I/99mTc, 123I/124I, and 99mTc/18F. Knowledge of both spatial distribution and kinetics of infection will allow for better understanding of oncolytic virotherapies and help to inform clinical practice and dose determination.
  • Simultaneous imaging of PET and SPECT tracers with both spatial and temporal co-registration makes the translation from preclinical to clinical tracers a one-to-one process.
  • The system enables radiovirotherapy with 131I and 188Re at high sub-mm resolution.
Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →

MILabs remotely installs from the Netherlands new E-Class PET/SPECT/CT at Osaka University of Pharmaceutical Sciences

Osaka, Japan and Utrecht, the Netherlands May 4th, 2020 In a world with COVID-19 travel …

Read More →

University of Torino (UNITO) acquires an advanced MILabs molecular imaging system

The University of Torino (UNITO) acquires advanced MILabs molecular imaging system for the design of …

Read More →

Truman VA acquires VECTor preclinical imaging system featuring exclusive multimodal synergy capabilities.

Columbia, Missouri, USA and Utrecht, the Netherlands April 9th, 2020 Harry S. Truman Memorial Veterans’ …

Read More →

Cyprus-based EPOS-Iasis acquires MILabs innovative Optical/CT system

Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals …

Read More →

MILabs enhances micro-CT for Coronavirus (COVID-19) research.

March 19, 2020 – Utrecht, the Netherlands Based on recent scientific research, diagnostic X-ray CT …

Read More →

The Julius Wolf Institute at the Charité installs mission-critical MILabs microCT for in-vivo studies of musculoskeletal regeneration

25 February 2020 – Berlin-Germany and Utrecht, Netherlands, The Julius Wolff Institute for Biomechanics and …

Read More →

MILabs realizes a breakthrough in preclinical oncology imaging by eliminating the positron range effect of 89Zr-immunoPET

February 15, 2020 – Utrecht, the Netherlands Researchers at MILabs B.V. have succeeded at imaging …

Read More →
Scroll to Top